Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression.
In a double-blind study lasting for 4 weeks, the authors compared the effectiveness of amoxapine, an antidepressant with potential antipsychotic properties, with a combination of amitriptyline plus perphenazine in the treatment of 38 patients who had the diagnosis of major depression with psychotic features (psychotic or delusional depression). Patients in each group showed similar improvement in depression and psychosis. There was a tendency for the patients treated with amitriptyline plus perphenazine to have higher global response rates. However, the patients given amoxapine had significantly fewer extrapyramidal side effects.
Medical University of South Carolina, Institute of Psychiatry, Charleston 29425.
R F
RF
Anton
E A
EA
Burch
D000328:Adult; D000639:Amitriptyline / Q000627:therapeutic use*; D000657:Amoxapine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003702:Delusions / Q000188:drug therapy / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010546:Perphenazine / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D003989:Dibenzoxazepines; D000639:Amitriptyline; D010546:Perphenazine; D000657:Amoxapine